Literature DB >> 25048343

Temporal trends in the occurrence and outcomes of atrial fibrillation in patients with acute myocardial infarction (from the Atherosclerosis Risk in Communities Surveillance Study).

Lindsay G S Bengtson1, Lin Y Chen2, Alanna M Chamberlain3, Erin D Michos4, Eric A Whitsel5, Pamela L Lutsey6, Sue Duval2, Wayne D Rosamond7, Alvaro Alonso6.   

Abstract

Atrial fibrillation (AF) frequently coexists in the setting of myocardial infarction (MI), being associated with increased mortality. Nonetheless, temporal trends in the occurrence of AF complicating MI and in the prognosis of these patients are not well described. We examined temporal trends in prevalence of AF in the setting of MI and the effect of AF on prognosis in the community. We studied a population-based sample of 20,049 validated first-incident nonfatal hospitalized MIs among 35- to 74-year old residents of 4 communities in the Atherosclerosis Risk in Communities (ARIC) Study from 1987 through 2009. Prevalence of AF in the setting of MI increased from 11% to 15% during the 23-year study period. The multivariable adjusted odds ratio for prevalent AF, per 5-year increment, was 1.11 (95% confidence interval 1.04 to 1.19). Overall, in patients with MI, AF was associated with increased 1-year case fatality (odds ratio 1.47, 95% confidence interval 1.07 to 2.01) compared with those without AF. However, there was no evidence that the impact of AF on MI survival changed over time or differed over time by sex, race, or MI classification (all p values >0.10). In conclusion, co-occurrence of AF in MI slightly increased between 1987 and 2009. The adverse impact of AF on survival in the setting of MI was consistent throughout. In the setting of MI, co-occurrence of AF should be viewed as a critical clinical event, and treatment needs unique to this population should be explored further.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25048343      PMCID: PMC4609175          DOI: 10.1016/j.amjcard.2014.05.059

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  27 in total

1.  Rivaroxaban in patients with a recent acute coronary syndrome.

Authors:  Jessica L Mega; Eugene Braunwald; Stephen D Wiviott; Jean-Pierre Bassand; Deepak L Bhatt; Christoph Bode; Paul Burton; Marc Cohen; Nancy Cook-Bruns; Keith A A Fox; Shinya Goto; Sabina A Murphy; Alexei N Plotnikov; David Schneider; Xiang Sun; Freek W A Verheugt; C Michael Gibson
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Acute management of ST-elevation myocardial infarction patients taking dabigatran.

Authors:  Jay Shavadia; Robert C Welsh
Journal:  Can J Cardiol       Date:  2013-09-08       Impact factor: 5.223

3.  Trends in incidence, severity, and outcome of hospitalized myocardial infarction.

Authors:  Véronique L Roger; Susan A Weston; Yariv Gerber; Jill M Killian; Shannon M Dunlay; Allan S Jaffe; Malcolm R Bell; Jan Kors; Barbara P Yawn; Steven J Jacobsen
Journal:  Circulation       Date:  2010-02-08       Impact factor: 29.690

4.  PREDICT: A simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: the Minnesota heart survey.

Authors:  D R Jacobs; C Kroenke; R Crow; M Deshpande; D F Gu; L Gatewood; H Blackburn
Journal:  Circulation       Date:  1999-08-10       Impact factor: 29.690

Review 5.  Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis.

Authors:  Patricia Jabre; Véronique L Roger; Mohammad H Murad; Alanna M Chamberlain; Larry Prokop; Frédéric Adnet; Xavier Jouven
Journal:  Circulation       Date:  2011-04-04       Impact factor: 29.690

6.  Population trends in the incidence and outcomes of acute myocardial infarction.

Authors:  Robert W Yeh; Stephen Sidney; Malini Chandra; Michael Sorel; Joseph V Selby; Alan S Go
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

7.  Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006.

Authors:  William J Rogers; Paul D Frederick; Edna Stoehr; John G Canto; Joseph P Ornato; C Michael Gibson; Charles V Pollack; Joel M Gore; Nisha Chandra-Strobos; Eric D Peterson; William J French
Journal:  Am Heart J       Date:  2008-11-01       Impact factor: 4.749

8.  Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.

Authors:  Morten Lamberts; Jonas Bjerring Olesen; Martin Huth Ruwald; Carolina Malta Hansen; Deniz Karasoy; Søren Lund Kristensen; Lars Køber; Christian Torp-Pedersen; Gunnar Hilmar Gislason; Morten Lock Hansen
Journal:  Circulation       Date:  2012-08-06       Impact factor: 29.690

9.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

10.  Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Alvaro Alonso; Sunil K Agarwal; Elsayed Z Soliman; Marietta Ambrose; Alanna M Chamberlain; Ronald J Prineas; Aaron R Folsom
Journal:  Am Heart J       Date:  2009-07       Impact factor: 4.749

View more
  6 in total

Review 1.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

2.  A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome.

Authors:  Bory Kea; Tahroma Alligood; Vincent Manning; Merritt Raitt
Journal:  Curr Emerg Hosp Med Rep       Date:  2016-07-06

3.  Prevalence and Spectrum of TBX5 Mutation in Patients with Lone Atrial Fibrillation.

Authors:  Zhan-Cheng Wang; Wen-Hui Ji; Chang-Wu Ruan; Xing-Yuan Liu; Xing-Biao Qiu; Fang Yuan; Ruo-Gu Li; Ying-Jia Xu; Xu Liu; Ru-Tai Huang; Song Xue; Yi-Qing Yang
Journal:  Int J Med Sci       Date:  2016-01-23       Impact factor: 3.738

4.  Effectiveness and safety of recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction in elderly in combination with cardiac failure.

Authors:  Hong Xu; Bosong Wang; Qingmei Meng; Jinlong Li; Weidong Sun; Li Xin; Liping Chen
Journal:  Pak J Med Sci       Date:  2017 May-Jun       Impact factor: 1.088

5.  Involvement of Autonomic Nervous System in New-Onset Atrial Fibrillation during Acute Myocardial Infarction.

Authors:  Audrey Sagnard; Charles Guenancia; Basile Mouhat; Maud Maza; Marie Fichot; Daniel Moreau; Fabien Garnier; Luc Lorgis; Yves Cottin; Marianne Zeller
Journal:  J Clin Med       Date:  2020-05-14       Impact factor: 4.241

6.  Trajectories of Cardiovascular Risk Factors and Incidence of Atrial Fibrillation Over a 25-Year Follow-Up: The ARIC Study (Atherosclerosis Risk in Communities).

Authors:  Faye L Norby; Elsayed Z Soliman; Lin Y Chen; Lindsay G S Bengtson; Laura R Loehr; Sunil K Agarwal; Alvaro Alonso
Journal:  Circulation       Date:  2016-08-23       Impact factor: 29.690

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.